These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 3051029)

  • 1. Do natural compounds need specific drug development?
    Simon P; Verry M
    Prog Clin Biol Res; 1988; 280():407-21. PubMed ID: 3051029
    [No Abstract]   [Full Text] [Related]  

  • 2. Experience with validation of clinical trial materials: an inspector's viewpoint.
    Wolfe L
    Dev Biol (Basel); 2003; 113():27-33. PubMed ID: 14620849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FEDESA's point of view: quality, application to IVMPs (immunological veterinary medicinal products).
    Soulebot JP
    Dev Biol Stand; 1992; 79():201-11. PubMed ID: 1286759
    [No Abstract]   [Full Text] [Related]  

  • 4. Recommendations and requirements for the design of bioanalytical testing used in comparability studies for biosimilar drug development.
    Cai XY; Gouty D; Baughman S; Ramakrishnan M; Cullen C
    Bioanalysis; 2011 Mar; 3(5):535-40. PubMed ID: 21388266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Problems raising from the control of biological products employed in medicine. Control of sera, vaccines, and biological products in France].
    Desbordes J
    Ann Ist Super Sanita; 1969; 5(3-4):218-81. PubMed ID: 16089166
    [No Abstract]   [Full Text] [Related]  

  • 6. Control of manufacture--the EC point of view.
    Meyer P
    Dev Biol Stand; 1992; 79():159-62. PubMed ID: 1286750
    [No Abstract]   [Full Text] [Related]  

  • 7. Control of manufacture--principles and purposes.
    Luff PR
    Dev Biol Stand; 1992; 79():155-8. PubMed ID: 1286749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products.
    Brodniewicz-Proba T
    Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological assays: their role in the development and quality control of recombinant biological medicinal products.
    Mire-Sluis AR; Gerrard T; Das RG; Padilla A; Thorpe R
    Biologicals; 1996 Dec; 24(4):351-62. PubMed ID: 9088552
    [No Abstract]   [Full Text] [Related]  

  • 10. Assessing the bioequivalence of biosimilars The Retacrit case.
    Schellekens H
    Drug Discov Today; 2009 May; 14(9-10):495-9. PubMed ID: 19429509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimum safety requirements for preclinical testing.
    Dorner F; Barrett PN; Schwartz HP; Eibl H
    Dev Biol Stand; 1993; 81():245-52. PubMed ID: 8174809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Who Expert Committee on Biological Standardization.
    World Health Organization
    World Health Organ Tech Rep Ser; 2004; 926():1-109. PubMed ID: 15918537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Product development of probiotics as biological drugs.
    Sutton A
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S128-32; discussion S144-51. PubMed ID: 18181718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproductive toxicology guidelines: comparison and application.
    Beltrame D; Mazué G
    Ann Ist Super Sanita; 1993; 29(1):3-14. PubMed ID: 8129269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars: opportunity or cause for concern?
    Roger SD; Mikhail A
    J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural products to drugs: natural product-derived compounds in clinical trials.
    Butler MS
    Nat Prod Rep; 2008 Jun; 25(3):475-516. PubMed ID: 18497896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Toxicology of reproduction: predictive value of experimental models. Round Table No 1 at Giens XIII].
    Guittin P; Soubrié C; Autret E; Boutemy C; Eléfant E; Jacqz-Aigrain E; Le Bigot JF; Marmor D; Marzin D; Pallardy M; Roux C; Saint Salvi B; Siou G; Soufir JC; Spézia F; Stadler J
    Therapie; 1998; 53(4):355-63. PubMed ID: 9806005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in natural health product research: The importance of standardization.
    Shan JJ; Rodgers K; Lai CT; Sutherland SK
    Proc West Pharmacol Soc; 2007; 50():24-30. PubMed ID: 18605225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WHO Expert Committee on Biological Standardization.
    World Health Organ Tech Rep Ser; 2002; 904():i-vi, 1-107. PubMed ID: 11980231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.